Home Featured Page 10

Featured

Latest

Dr Ros Watts – Building Communities and Connection

The Psychedelic News Feed: October 27 – November 02, 2025

Compass Pathways Accelerates Psilocybin Launch Timeline by 9-12 Months

CLOSING RECEPTION Travis Gillan’s Revelator

Pα+ Psychedelic Bulletin #212: Delix Posts Early Efficacy Signal; NRx Wants FDA to Ban Competitors’ Ketamine; Cybin Raises $175M

Dylan Beynon – Mindbloom – At Home Ketamine

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

Beckley and atai Leadership Unpack Phase 2b Data, Take Aim at...

Beyond the Endpoint: Industry Voices Reflect on Compass’ Phase 3 Readout

It’s Time to Push Back: Meta’s War on Psychedelic Voices

Victoria Litman – The Future of Psychedelic Regulation Is Local

Pα+ Psychedelic Bulletin #202: Psychedelics Access ‘Within 12 Months’, RFK Jr....

Cautious Optimism, Lingering Questions: Researchers React to Compass’ Phase 3 Psilocybin...

Compass Pathways’ Psilocybin Clears First Phase 3 Hurdle

1...91011...301 Page 10 of 301

Dr Ros Watts – Building Communities and Connection

The Psychedelic News Feed: October 27 – November 02, 2025

Compass Pathways Accelerates Psilocybin Launch Timeline by 9-12 Months

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Dr Ros Watts – Building Communities and Connection

The Psychedelic News Feed: October 27 – November 02, 2025

Compass Pathways Accelerates Psilocybin Launch Timeline by 9-12 Months

CLOSING RECEPTION Travis Gillan’s Revelator

Pα+ Psychedelic Bulletin #212: Delix Posts Early Efficacy Signal; NRx Wants FDA to Ban Competitors’ Ketamine; Cybin Raises $175M

Dylan Beynon – Mindbloom – At Home Ketamine

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

Beckley and atai Leadership Unpack Phase 2b Data, Take Aim at...

Beyond the Endpoint: Industry Voices Reflect on Compass’ Phase 3 Readout

It’s Time to Push Back: Meta’s War on Psychedelic Voices

Victoria Litman – The Future of Psychedelic Regulation Is Local

Pα+ Psychedelic Bulletin #202: Psychedelics Access ‘Within 12 Months’, RFK Jr....

Cautious Optimism, Lingering Questions: Researchers React to Compass’ Phase 3 Psilocybin...

Compass Pathways’ Psilocybin Clears First Phase 3 Hurdle

EDITOR PICKS

Dr Ros Watts – Building Communities and Connection

The Psychedelic News Feed: October 27 – November 02, 2025

Compass Pathways Accelerates Psilocybin Launch Timeline by 9-12 Months

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY